Endocrinology and Aging

Williams Textbook of Endocrinology, Twelfth Edition

Volumn , Issue , 2011, Pages 1219-1233

  Lamberts, Steven W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85170164153     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0324-5.00027-4     Document Type: Chapter

References (144)

1. J Oeppen and JW Vaupel (2002) Demography: broken limits to life expectancy. Science 296 1029.
2. EW Campion (1994) The oldest old. N Engl J Med 330 1819.
3. MR Kosorok, GS Omenn, P Diehr, et al. (1992) Restricted activity days among older adults. Am J Public Health 82 1263.
4. JF Fries (1980) Aging, natural death, and the compression of morbidity. N Engl J Med 303 130.
5. AJ Vita, RB Terry, HB Hubert, et al. (1998) Aging, health risks, and cumulative disability. N Engl J Med 338 1035.
6. D Rudman and MP Rao (1992) Serum insulin-like growth factor I in healthy older men in relation to physical activity. JE Morley, SG Korenman,(Eds) Endocrinology and Metabolism in the Elderly Oxford: Blackwell Scientific 50.
7. DM Buchner and EH Wagner (1992) Preventing frail health. Clin Geriatr Med 8 1.
8. ME Tinetti, M Speechley and SF Ginter (1988) Risk factors for falls among elderly persons living in the community. N Engl J Med 319 1701.
9. DA Kallman, CC Plato and JD Tobin (1990) The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol 45 M82.
10. MA Fiatarone, EF O'Neill, ND Ryan, et al. (1994) Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 330 1769.
11. JM Guralnik, L Ferrucci, EM Simonsick, et al. (1995) Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 332 556.
12. AL Peters and MB Davidson (1997) Aging and diabetes. KGMM Alberti, P Zimmet, RA Defrozo, H Keen,(Eds) International Textbook of Diabetes Mellitus Chichester, UK: John Wiley & Sons 1151.
13. S Mariotti, C Franceschi, A Cossarizza and A Pinchera (1995) The aging thyroid. Endocr Rev 16 686.
14. MI Surks, E Ortiz, GH Daniels, et al. (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291 228.
15. J Gussekloo, E van Exel, AJ de Craen, et al. (2004) Thyroid status, disability and cognitive function, and survival in old age. JAMA 292 2591.
16. AW van den Beld, TJ Visser, RA Feelders, et al. (2005) Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab 90 6403.
17. S Mariotti (2005) Thyroid function and aging: do serum 3,5,3′-triiodothyronine and thyroid-stimulating hormone concentrations give the Janus response? J Clin Endocrinol Metab 90 6735.
18. S Mariotti (2008) Mild hypothyroidism and ischemic heart disease: is age the answer? J Clin Endocrinol Metab 93 2969.
19. PM Wise, KM Krajnak and ML Kashon (1996) Menopause: the aging of multiple pacemakers. Science 273 67.
20. A Vermeulen (1991) Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab 73 221.
21. SM Harman and PD Tsitouras (1980) Reproductive hormones in aging men: I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 51 35.
22. SM Harman, PD Tsitouras, PT Costa, et al. (1982) Reproductive hormones in aging men: II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 54 547.
23. J Herbert (1995) The age of dehydroepiandrosterone. Lancet 345 1193.
24. G Ravaglia, P Forti, F Maioli, et al. (1996) The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old: results from an Italian study on healthy free-living over-ninety-year-olds. J Clin Endocrinol Metab 81 1173.
25. PJ Hornsby (1995) Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann N Y Acad Sci 774 29.
26. E Corpas, SM Harman, MA Pineyro, et al. (1992) Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 75 530.
27. MR Blackman (1987) Pituitary hormones and aging. Endocrinol Metab Clin North Am 16 981.
28. C Wang, RS Swedloff, A Iranmanesh, et al. (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 85 2839.
29. AF Attanasio, SW Lamberts, AM Matranga, et al. (1997) Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 82 82.
30. E Barrett-Connor (1998) Hormone replacement therapy. BMJ 317 457.
31. D Grady, SM Rubin, DB Petitti, et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117 1016.
32. E Barrett-Connor and D Grady (1998) Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19 55.
33. F Grodstein, JE Manson, GA Colditz, et al. (2000) A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133 933.
34. JE Rossouw, GL Anderson, RL Prentice, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 321.
35. GL Anderson, M Limacher, AR Assaf, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 1701.
36. CM Viscoli, LM Brass, WN Kernan, et al. (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345 1243.
37. N Cherry, K Gilmour, P Hannaford, et al. (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360 2001.
38. S Hulley, D Grady, T Bush, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280 605.
39. RK Dubey, B Imthurn, LC Zacharia, et al. (2004) Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 44 789.
40. HB Peterson, SB Thacker, PS Corso, et al. (2004) Hormone therapy: making decisions in the face of uncertainty. Arch Intern Med 164 2308.
41. JE Manson, MA Allison, JE Rossouw, et al. (2007) Estrogen therapy and coronary-artery calcification. N Engl J Med 356 2591.
42. LK Weiss, RT Burkman, KL Cushing-Haugen, et al. (2002) Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 100 1148.
43. CI Li, KE Malone, PL Porter, et al. (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 3254.
44. RT Chlebowski, SL Hendrix, RD Langer, et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 3243.
45. V Beral (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 419.
46. SA Shumaker, C Legault, L Kuller, et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 2947.
47. HN Hodis (2008) Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleve Clin J Med 75(suppl 4), S3.
48. J Hays, JK Ockene, RL Brunner, et al. (2003) Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348 1839.
49. WH Utian, D Shoupe, G Bachmann, et al. (2001) Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75 1065.
50. RJ Santen (1996) Long-term tamoxifen therapy: can an antagonist become an agonist? J Clin Endocrinol Metab 81 2027.
51. DJ Grainger and JC Metcalfe (1996) Tamoxifen: teaching an old drug new tricks? Nat Med 2 381.
52. AB Grey, JP Stapleton, MC Evans, et al. (1995) The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 99 636.
53. MW Draper, DE Flowers, WJ Huster, et al. (1996) A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11 835.
54. S Palacios (2007) The future of the new selective estrogen receptor modulators. Menopause Int 13 27.
55. PD Delmas, NH Bjarnason, BH Mitlak, et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 1641.
56. B Ettinger, DM Black, BH Mitlak, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 637.
57. E Seeman, GG Crans, A Diez-Perez, et al. (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17 313.
58. E Barrett-Connor, L Mosca, P Collins, et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 125.
59. L Mosca, D Grady, E Barrett-Connor, et al. (2009) Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 40 147.
60. GC Davies, WJ Huster, Y Lu, et al. (1999) Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 93 558.
61. A Howell (2008) The endocrine prevention of breast cancer. Best Pract Res Clin Endocrinol Metab 22 615.
62. S Martino, JA Cauley, E Barrett-Connor, et al. (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 1751.
63. VG Vogel, JP Costantino, DL Wickerham, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 2727.
64. W Shelly, MW Draper, V Krishnan, et al. (2008) Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 63 163.
65. MD Moen and GM Keating (2008) Raloxifene: a review of its use in the prevention of invasive breast cancer. Drugs 68 2059.
66. SR Cummings, B Ettinger, PD Delmas, et al. (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359 697.
67. SR Davis, SL Davison, S Donath, et al. (2005) Circulating androgen levels and self-reported sexual function in women. JAMA 294 91.
68. SR Davis, M Moreau, R Kroll, et al. (2008) Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 359 2005.
69. JE Rossouw (2008) Postmenopausal hormone therapy for disease prevention: have we learned any lessons from the past? Clin Pharmacol Ther 83 14.
70. RL Tannen, MG Weiner, D Xie, et al. (2008) Perspectives on hormone replacement therapy: the Women's Health Initiative and new observational studies sampling the overall population. Fertil Steril 90 258.
71. EG Nabel (2000) Coronary heart disease in women: an ounce of prevention. N Engl J Med 343 572.
72. JS Tenover (1994) Androgen administration to aging men. Endocrinol Metab Clin North Am 23 877.
73. A Vermeulen and JM Kaufman (2002) Diagnosis of hypogonadism in the aging male. Aging Male 5 170.
74. SM Harman, EJ Metter, JD Tobin, et al. (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86 724.
75. AB Araujo, GR Esche, V Kupelian, et al. (2007) Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 92 4241.
76. RI McLachlan and CA Allan (2004) Defining the prevalence and incidence of androgen deficiency in aging men: where are the goal posts? J Clin Endocrinol Metab 89 5916.
77. FC Wu, A Tajar, SR Pye, et al. (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93 2737.
78. RD Jones, JE Nettleship, D Kapoor, et al. (2005) Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 5 141.
79. GA Laughlin, E Barrett-Connor and J Bergstrom (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93 68.
80. C Wang, DR Eyre, R Clark, et al. (1996) Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 81 3654.
81. S Bhasin, TW Storer, N Berman, et al. (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335 1.
82. PJ Snyder, H Peachey, P Hannoush, et al. (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84 1966.
83. PJ Snyder, H Peachey, P Hannoush, et al. (1999) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84 2647.
84. CK Pearlman and LI Kobashi (1972) Frequency of intercourse in men. J Urol 107 298.
85. ER Bolona, MV Uraga, RM Haddad, et al. (2007) Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82 20.
86. S Bhasin and WJ Bremner (1997) Clinical review 85. Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 82 3.
87. CJ Bagatell and WJ Bremner (1996) Androgens in men: uses and abuses. N Engl J Med 334 707.
88. S Bhasin, GR Cunningham, FJ Hayes, et al. (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91 1995.
89. OM Calof, AB Singh, ML Lee, et al. (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60 1451.
90. PY Liu, RS Swerdloff and JD Veldhuis (2004) Clinical review 171. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 89 4789.
91. S Bhasin, CJ Bagatell, WJ Bremner, et al. (1998) Issues in testosterone replacement in older men. J Clin Endocrinol Metab 83 3435.
92. JE Morley and S Melmed (1979) Gonadal dysfunction in systemic disorders. Metabolism 28 1051.
93. A Gray, HA Feldman, JB McKinlay, et al. (1991) Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73 1016.
94. A Negro-Vilar (1999) Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 84 3459.
95. M Zitzmann and E Nieschlag (2003) The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 26 76.
96. K Krithivas, SM Yurgalevitch, BA Mohr, et al. (1999) Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol 162 137.
97. E Giovannucci, EA Platz, MJ Stampfer, et al. (1999) The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 53 121.
98. IT Huhtaniemi, SR Pye, KL Limer, et al. (2009) Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab 94 277.
99. F Labrie, V Luu-The, SX Lin, et al. (2000) Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 25 1.
100. F Labrie, A Belanger, J Simard, et al. (1995) DHEA and peripheral androgen and estrogen formation: intracinology. Ann N Y Acad Sci 774 16.
101. E Barrett-Connor and D Goodman-Gruen (1995) The epidemiology of DHEAS and cardiovascular disease. Ann N Y Acad Sci 774 259.
102. S Kalmijn, LJ Launer, RP Stolk, et al. (1998) A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J Clin Endocrinol Metab 83 3487.
103. P Smit, RH van Schaik, M van der Werf, et al. (2005) A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 90 5313.
104. W Arlt, F Callies, JC van Vlijmen, et al. (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341 1013.
105. AJ Morales, JJ Nolan, JC Nelson, et al. (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78 1360.
106. SS Yen, AJ Morales and O Khorram (1995) Replacement of DHEA in aging men and women:. potential remedial effects. Ann N Y Acad Sci 774 128.
107. KS Nair, RA Rizza, P O'Brien, et al. (2006) DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355 1647.
108. EE Baulieu, G Thomas, S Legrain, et al. (2000) Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 97 4279.
109. M Muller, AW van den Beld, YT van der Schouw, et al. (2006) Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J Clin Endocrinol Metab 91 3988.
110. CM Jankowski, WS Gozansky, JM Kittelson, et al. (2008) Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab 93 4767.
111. AA Skolnick (1996) Scientific verdict still out on DHEA. JAMA 276 1365.
112. PM Stewart (2006) Aging and fountain-of-youth hormones. N Engl J Med 355 1724.
113. AA Toogood, PA O'Neill and SM Shalet (1996) Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 81 460.
114. AA Toogood, J Jones, PA O'Neill, MO Thorner, et al. (1998) The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. Clin Endocrinol (Oxf) 48 569.
115. SE Borst, WJ Millard and DT Lowenthal (1994) Growth hormone, exercise, and aging: the future of therapy for the frail elderly. J Am Geriatr Soc 42 528.
116. R Nass, RM Huber, V Klauss, et al. (1995) Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 80 552.
117. F Salomon, RC Cuneo, R Hesp, et al. (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321 1797.
118. D Rudman, AG Feller, HS Nagraj, et al. (1990) Effects of human growth hormone in men over 60 years old. N Engl J Med 323 1.
119. D Rudman, AG Feller, L Cohn, et al. (1991) Effects of human growth hormone on body composition in elderly men. Horm Res 36(suppl 1), 73.
120. DR Taaffe, L Pruitt, J Reim, et al. (1994) Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 79 1361.
121. KE Yarasheski, JJ Zachwieja, JA Campbell, et al. (1995) Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol 268(2 Pt 1), E268.
122. MA Papadakis, D Grady, D Black, et al. (1996) Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124 708.
123. H Liu, DM Bravata, I Olkin, et al. (2007) Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146 104.
124. MR Blackman, JD Sorkin, T Munzer, et al. (2002) Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288 2282.
125. MG Giannoulis, PH Sonksen, M Umpleby, et al. (2006) The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab 91 477.
126. DN Herndon, RE Barrow, KR Kunkel, et al. (1990) Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg 212 424.
127. IM Chapman, ML Hartman, SS Pezzoli, et al. (1996) Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults: a clinical research center study. J Clin Endocrinol Metab 81 2874.
128. IM Chapman, MA Bach, E Van Cauter, et al. (1996) Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 81 4249.
129. RG Smith, H Jiang and Y Sun (2005) Developments in ghrelin biology and potential clinical relevance. Trends Endocrinol Metab 16 436.
130. R Nass, SS Pezzoli, MC Oliveri, et al. (2008) Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 149 601.
131. HK White, CD Petrie, W Landschulz, et al. (2009) Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 94 1198.
132. JM Chan, MJ Stampfer, E Giovannucci, et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563.
133. SE Hankinson, WC Willett, GA Colditz, et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 1393.
134. J Ma, MN Pollak, E Giovannucci, et al. (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91 620.
135. TT Perls, NR Reisman and SJ Olshansky (2005) Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. JAMA 294 2086.
136. SJ Olshansky and TT Perls (2008) New developments in the illegal provision of growth hormone for “anti-aging” and bodybuilding. JAMA 299 2792.
137. SM Shalet (2000) GH deficiency in the elderly: the case for GH replacement. Clin Endocrinol (Oxf) 53 279.
138. JW Rowe and RL Kahn (1987) Human aging: usual and successful. Science 237 143.
139. WR Hazzard (1995) Weight control and exercise: cardinal features of successful preventive gerontology. JAMA 274 1964.
140. Healthy People 2000: National and Health Promotion and Disease Prevention Objectives Washington DC: Government Printing Office
141. SW Lamberts, AW van den Beld and AJ van der Lely (1997) The endocrinology of aging. Science 278 419.
142. Reference deleted in proofs.
143. Reference deleted in proofs.
144. Reference deleted in proofs.